Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain malignancy. Even when subjected to multimodal treatment using surgery, chemo- and radiotherapy, the majority of GBM patients die within a year after diagnosis. Affinity targeting of anti-glioma drugs to malignant lesions, in particular to disseminated cells hiding behind the blood-brain-barrier, may dramatically improve efficacy of antiglioma therapies. Upon intravenous administration, tumor penetrating peptides (TPP-s) home to malignant lesions and extravasate into tumor parenchyma. Interestingly, these peptides retain their activity to penetrate excised tumor explants in short-term ex vivo assays. Here, we report development of an in vitro 3D penetration assay of homing peptide-functionalized silver nanoparticles (AgNP) in U87 glioma spheroids. U87 spheroids were incubated with fluorescent silver nanoparticles functionalized with prototypic tumor penetrating peptides, iRGD (CRGDKGPDC) and RPARPAR, or control peptides. Subsequently, spheroids were incubated with a non-toxic etching solution that selectively removes the extracellular AgNP with no effect on internalized AgNP. Fluorescence imaging and Matlab -based quantitative analysis of spheroid cryosections and of live spheroids was used to assess distribution of AgNP with and without etching treatment. Compared to control nanoparticles, iRGD and RPARPAR functionalized AgNP showed dramatically increased binding and penetration of the particles in the U87 spheroids. The binding was inhibited by peptide receptor-blocking anti NRP-1 and anti-av-integrin antibodies (but not by control antibodies), suggesting specific effect of AgNP surface peptides. Establishment and validation of 3D in vitro tumor spheroid penetration assay may provide a standardized system for evaluation tumor homing and penetration ability of homing peptides and to allow medium- throughput mechanistic and experimental therapy studies.
. 2015 Nov 9;17(Suppl 5):v77. doi: 10.1093/neuonc/nov212.19
DDEL-19: PENETRATION OF HOMING PEPTIDE-FUNCTIONALIZED NANOPARTICLES TO GLIOMA SPHEROIDS IN VITRO
Kadri Toome
1, Anne-Mari Anton Willmore
1, Pille Säälik
1, Gary B Braun
2, Ramsey Majzoub
3, Cyrus R Safinya
3, Rolf Bjerkvig
4, Tambet Teesalu
1,2
Kadri Toome
1Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia
Find articles by Kadri Toome
Anne-Mari Anton Willmore
1Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia
Find articles by Anne-Mari Anton Willmore
Pille Säälik
1Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia
Find articles by Pille Säälik
Gary B Braun
2Cancer Research Center, Sanford-Burnham Medical Research Institute, La Jolla, CA, USA
Find articles by Gary B Braun
Ramsey Majzoub
3Department of Physics, Department of Materials, and Molecular, Cellular and Developmental Biology Department, University of California, Santa Barbara, Santa Barbara, CA, USA
Find articles by Ramsey Majzoub
Cyrus R Safinya
3Department of Physics, Department of Materials, and Molecular, Cellular and Developmental Biology Department, University of California, Santa Barbara, Santa Barbara, CA, USA
Find articles by Cyrus R Safinya
Rolf Bjerkvig
4Department of Biomedicine, Univesity of Bergen, Bergen, Norway
Find articles by Rolf Bjerkvig
Tambet Teesalu
1Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia
2Cancer Research Center, Sanford-Burnham Medical Research Institute, La Jolla, CA, USA
Find articles by Tambet Teesalu
1Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia
2Cancer Research Center, Sanford-Burnham Medical Research Institute, La Jolla, CA, USA
3Department of Physics, Department of Materials, and Molecular, Cellular and Developmental Biology Department, University of California, Santa Barbara, Santa Barbara, CA, USA
4Department of Biomedicine, Univesity of Bergen, Bergen, Norway
Issue date 2015 Nov.
Published by Oxford University Press on behalf of the Society for Neuro-Oncology 2015.
PMCID: PMC4638740
